Low serum lathosterol levels associate with fatal cardiovascular disease and excess all-cause mortality: a prospective cohort study.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 09 01 2019
accepted: 28 03 2019
pubmed: 6 4 2019
medline: 15 4 2020
entrez: 6 4 2019
Statut: ppublish

Résumé

A more precise identification of patients at "high cardiovascular risk" is preeminent in cardiovascular risk stratification. To investigate the relationships between markers of cholesterol homeostasis, cardiovascular events and all-cause mortality. We quantified markers of cholesterol homeostasis by gas chromatography-mass spectrometry in 377 subjects with suspected coronary artery disease, who were not on lipid-lowering drugs at baseline. All patients were followed for occurrence of cardiovascular events and mortality over a period of 4.9 +/- 1.7 years. The standardized mortality ratio (SMR) was calculated as the ratio of the observed and the expected deaths based on the death rates of the Regional Databases Germany, and Poisson regression (rate ratio, RR) was used to compare subgroups. The SMR and RR were standardized for sex, age category and calendar period. In addition, Cox regression (Hazard ratio, HR) was used to determine the effect of co-variables on (cardiovascular) mortality within the cohort. Cardiovascular events, cardiovascular mortality and all-cause mortality. A total of 42 deaths were observed in 1818 person-years corresponding with an SMR of 0.99 (95% CI 0.71-1.33; p = 0.556). A fatal cardiovascular event occurred in 26 patients. Lower levels of lathosterol were associated with increased cardiovascular mortality (HR 1.59; 95% CI: 1.16-2.17; p = 0.004) and excess all-cause mortality (HR 1.41; 95% CI: 1.09-1.85; p = 0.011). Lower lathosterol tertile compared to the adjacent higher tertile was associated with 1.6 times higher all-cause mortality risk (RR 1.60; 95% CI 1.07-2.40; p for trend = 0.022). This corresponded with a 2.3 times higher mortality risk of a lathosterol-LDL ratio equal to or below the median (RR 2.29; 95% CI 1.19-4.43; p = 0.013). None of the other cholesterol homeostasis markers were associated with cardiovascular and all-cause mortality. In patients not on lipid-lowering agents, low serum lathosterol correlated with increased risk of cardiovascular events and excess all-cause mortality.

Identifiants

pubmed: 30949753
doi: 10.1007/s00392-019-01474-2
pii: 10.1007/s00392-019-01474-2
doi:

Substances chimiques

Biomarkers 0
lathosterol 80-99-9
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1381-1385

Subventions

Organisme : Unilever (GB)
ID : 545372

Références

Coron Artery Dis. 2009 Sep;20(6):376-82
pubmed: 19620855
Atherosclerosis. 2010 Jun;210(2):362-5
pubmed: 20116793
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 15;957:116-22
pubmed: 24674990
BMJ. 1998 Apr 11;316(7138):1127-30
pubmed: 9552949
J Lipid Res. 2009 Sep;50(9):1927-35
pubmed: 19436064
Lancet. 2015 Apr 11;385(9976):1397-405
pubmed: 25579834
Proc Natl Acad Sci U S A. 1973 Jul;70(7):2162-6
pubmed: 4352976
J Lipid Res. 2009 Apr;50(4):730-9
pubmed: 19043140
J Am Coll Cardiol. 2012 Oct 16;60(16):1512-20
pubmed: 22999728
Atherosclerosis. 2018 Jul;274:139-145
pubmed: 29772482
J Am Coll Cardiol. 2016 Jul 19;68(3):325-326
pubmed: 27417013
J Pharmacol Exp Ther. 2006 Mar;316(3):1146-52
pubmed: 16282522
J Lipid Res. 2010 Aug;51(8):2384-93
pubmed: 20228406
Clin Res Cardiol. 2019 May;108(5):487-509
pubmed: 30302558
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290

Auteurs

Oliver Weingärtner (O)

Klinik für Innere Medizin I, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Germany. oliver.weingaertner@med.uni-jena.de.
Abteilung für Kardiologie, Klinikum Oldenburg, European Medical School Oldenburg-Groningen, Oldenburg, Germany. oliver.weingaertner@med.uni-jena.de.

Dieter Lütjohann (D)

Klinik für Innere Medizin I, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Germany.
Institut für Klinische Pharmakologie und Klinische Chemie, Universitätsklinikum Bonn, Bonn, Germany.

Sven Meyer (S)

Abteilung für Kardiologie, Klinikum Oldenburg, European Medical School Oldenburg-Groningen, Oldenburg, Germany.

Arne Fuhrmann (A)

Institut für Klinische Pharmakologie und Klinische Chemie, Universitätsklinikum Bonn, Bonn, Germany.

Bodo Cremers (B)

Klinik für Innere Medizin III, Abteilung für Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Sarah Seiler-Mußler (S)

Klinik für Innere Medizin IV, Abteilung für Nieren-und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Hans-F Schött (HF)

Institut für Klinische Pharmakologie und Klinische Chemie, Universitätsklinikum Bonn, Bonn, Germany.
Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund, Germany.

Anja Kerksiek (A)

Institut für Klinische Pharmakologie und Klinische Chemie, Universitätsklinikum Bonn, Bonn, Germany.

Silvia Friedrichs (S)

Institut für Klinische Pharmakologie und Klinische Chemie, Universitätsklinikum Bonn, Bonn, Germany.

Ursula Ulbricht (U)

Klinik für Innere Medizin IV, Abteilung für Nieren-und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Adam Zawada (A)

Klinik für Innere Medizin IV, Abteilung für Nieren-und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Ulrich Laufs (U)

Klinik für Innere Medizin III, Abteilung für Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

P Christian Schulze (PC)

Klinik für Innere Medizin I, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Germany.

Bruno Scheller (B)

Klinik für Innere Medizin III, Abteilung für Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Danilo Fliser (D)

Klinik für Innere Medizin IV, Abteilung für Nieren-und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Michael Böhm (M)

Klinik für Innere Medizin III, Abteilung für Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Eric Sijbrands (E)

Department of Vascular Genetics, Department of Internal Medicine, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.

Gunnar H Heine (GH)

Klinik für Innere Medizin IV, Abteilung für Nieren-und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH